Daniel Drucker
Daniel Drucker is a Canadian scientist credited with identifying GLP-1, the peptide that underlies the mechanism of Ozempic, and he predicts that future developments will make these weight loss medications more accessible.
Global Media Ratings
Countries Mentioned
| Country | Mentions | Sentiment | Dominance | + Persistence | x Population | = Reach | x GDP (millions) | = Power |
|---|---|---|---|---|---|---|---|---|
| Canada | 1 | 9.00 | 0.04% | +0% | 38,005,238 | 16,891 | $1,700,000 | 756$ |
| Totals | 1 | 38,005,238 | 16,891 | $1,700,000 | 756$ |
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
Canada:
Dr. Daniel Drucker was among five researchers jointly awarded a US$3-million Breakthrough Prize in Life Sciences for discoveries leading to the development of a class of drugs that are now widely used in the treatment of Type 2 diabetes and obesity.
9
Spain:
Daniel Drucker was the first to identify GLP-1 and discusses future accessibility of weight loss medications.
5